CN100393706C - 具有抗病毒性能的取代二氢喹唑啉 - Google Patents

具有抗病毒性能的取代二氢喹唑啉 Download PDF

Info

Publication number
CN100393706C
CN100393706C CNB2004800119284A CN200480011928A CN100393706C CN 100393706 C CN100393706 C CN 100393706C CN B2004800119284 A CNB2004800119284 A CN B2004800119284A CN 200480011928 A CN200480011928 A CN 200480011928A CN 100393706 C CN100393706 C CN 100393706C
Authority
CN
China
Prior art keywords
alkyl
group
compound
trifluoromethyl
expression hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2004800119284A
Other languages
English (en)
Chinese (zh)
Other versions
CN1784390A (zh
Inventor
T·温伯格
J·鲍梅斯特
U·贝茨
M·耶斯克
T·兰佩
S·尼科利克
J·里夫施莱格
R·肖赫-罗普
F·叙斯迈尔
H·齐默曼
R·格罗泽尔
K·亨宁格尔
G·休利特
J·克尔德尼希
D·朗
P·内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aic246 Jsc
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100393706(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Publication of CN1784390A publication Critical patent/CN1784390A/zh
Application granted granted Critical
Publication of CN100393706C publication Critical patent/CN100393706C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB2004800119284A 2003-05-02 2004-04-17 具有抗病毒性能的取代二氢喹唑啉 Expired - Lifetime CN100393706C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline
DE10319612.9 2003-05-02

Publications (2)

Publication Number Publication Date
CN1784390A CN1784390A (zh) 2006-06-07
CN100393706C true CN100393706C (zh) 2008-06-11

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800119284A Expired - Lifetime CN100393706C (zh) 2003-05-02 2004-04-17 具有抗病毒性能的取代二氢喹唑啉

Country Status (38)

Country Link
US (4) US7196086B2 (https=)
EP (1) EP1622880B3 (https=)
JP (1) JP4733631B2 (https=)
KR (1) KR100927063B1 (https=)
CN (1) CN100393706C (https=)
AR (1) AR044078A1 (https=)
AT (1) ATE355280T1 (https=)
AU (1) AU2004233978B2 (https=)
BR (1) BRPI0410029B8 (https=)
CA (1) CA2524069C (https=)
CL (1) CL2004000930A1 (https=)
CO (1) CO5700764A2 (https=)
CY (2) CY1106476T1 (https=)
DE (2) DE10319612A1 (https=)
DK (1) DK1622880T6 (https=)
EC (1) ECSP056138A (https=)
EG (1) EG25273A (https=)
ES (1) ES2284007T7 (https=)
FR (1) FR18C1029I2 (https=)
HN (1) HN2004000146A (https=)
HU (2) HUS1800018I1 (https=)
IL (1) IL171513A (https=)
MA (1) MA27794A1 (https=)
MX (1) MXPA05011707A (https=)
MY (1) MY144616A (https=)
NL (1) NL300933I2 (https=)
NO (2) NO333265B3 (https=)
NZ (1) NZ543317A (https=)
PE (1) PE20050145A1 (https=)
PL (1) PL1622880T6 (https=)
PT (1) PT1622880E (https=)
RU (1) RU2360912C2 (https=)
SI (1) SI1622880T1 (https=)
TW (1) TWI335912B (https=)
UA (1) UA82519C2 (https=)
UY (1) UY28294A1 (https=)
WO (1) WO2004096778A1 (https=)
ZA (1) ZA200508710B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101673A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
MX373764B (es) * 2013-06-19 2020-03-24 Aic246 Ag & Co Kg Letermovir amorfo y formulaciones farmaceuticas solidas del mismo para administracion por via oral.
WO2015088931A1 (en) * 2013-12-12 2015-06-18 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
WO2017091453A1 (en) * 2015-11-24 2017-06-01 Merck Sharp & Dohme Corp. Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts
ES2882531T3 (es) * 2016-08-08 2021-12-02 Phaeno Therapeutics Co Ltd Compuesto anti-virus CMVH
CN111741960B (zh) * 2018-02-08 2021-06-25 南京明德新药研发有限公司 一种3,4-二氢噻吩并[3,2-d]嘧啶类化合物的晶型及其制备方法
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
CA3112326A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
KR20250127350A (ko) 2019-09-26 2025-08-26 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물
UY39095A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39097A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
AR121439A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
PY2116987A (es) * 2020-02-27 2021-12-01 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
PY2116992A (es) 2020-02-27 2022-04-05 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
CA3189271A1 (en) 2020-08-17 2022-02-24 Girij Pal Singh A precipitation process for amorphous letermovir
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
WO2023185597A1 (zh) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用
PY24113872A (es) 2023-12-21 2025-07-29 Aic 246 Ag & Co Kg Sales diastereoméricas de aminoalchohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica.-

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A2 (en) * 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
EA200000840A1 (ru) 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
AU765203B2 (en) 1999-04-19 2003-09-11 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
JP4180365B2 (ja) * 2000-07-31 2008-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペラジン誘導体
RU2003133750A (ru) 2001-04-19 2005-05-10 Байер АГ (DE) Арилсульфонамиды в качестве антивирусных агентов
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) * 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
JP5139083B2 (ja) * 2005-01-25 2013-02-06 プロレキシーズ ファーマシューティカルズ インコーポレイテッド 抗腫瘍剤としてのキノキサリン誘導体
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
ES2336603T3 (es) * 2005-07-21 2010-04-14 F. Hoffmann-La Roche Ag Compuestos de pirido(2,3-d)pirimidina-2,4-diamina como inhibidores de ptp1b.
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
MX373764B (es) * 2013-06-19 2020-03-24 Aic246 Ag & Co Kg Letermovir amorfo y formulaciones farmaceuticas solidas del mismo para administracion por via oral.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A2 (en) * 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Benzothiadiazine dioxide human cytomegalovirusinhibitors:Synthesis and antiviral evaluation of mainheterocycle modified derivatives. MARTINEZ,ANA ET AL:.ANTIVIRAL CHEMISTRY & CHEMOTHERAPY,Vol.14 No.2. 2003 *
The anticytomegaloviral activity of raltitrexed is abrogatedinquiescent mouse fibroblasrs that overexpressthymidylatesynthase. GRIBAUDO,G.ET AL:.VIRUS RESEARCH,Vol.73 No.1. 2001 *

Also Published As

Publication number Publication date
RU2360912C2 (ru) 2009-07-10
USRE49698E1 (en) 2023-10-17
MA27794A1 (fr) 2006-03-01
US20050065160A1 (en) 2005-03-24
NO20055649L (no) 2006-01-31
PE20050145A1 (es) 2005-05-22
NO333265B1 (no) 2013-04-22
KR100927063B1 (ko) 2009-11-13
DE502004003052D1 (de) 2007-04-12
CY2018019I2 (el) 2018-12-12
MY144616A (en) 2011-10-14
ZA200508710B (en) 2006-12-27
ECSP056138A (es) 2006-04-19
DE10319612A1 (de) 2004-11-18
TWI335912B (en) 2011-01-11
BRPI0410029A (pt) 2006-04-25
HUS1800028I1 (hu) 2018-07-30
KR20060009883A (ko) 2006-02-01
AR044078A1 (es) 2005-08-24
HN2004000146A (es) 2008-06-24
HK1092463A1 (zh) 2007-02-09
RU2005137276A (ru) 2006-07-27
UA82519C2 (uk) 2008-04-25
NO333265B3 (no) 2019-06-03
TW200510343A (en) 2005-03-16
FR18C1029I2 (fr) 2020-07-17
BRPI0410029B1 (pt) 2019-12-31
CN1784390A (zh) 2006-06-07
IL171513A (en) 2011-11-30
US20070191387A1 (en) 2007-08-16
NO20055649D0 (no) 2005-11-30
US8513255B2 (en) 2013-08-20
HUS1800018I1 (hu) 2018-05-28
AU2004233978A1 (en) 2004-11-11
USRE46791E1 (en) 2018-04-17
CA2524069A1 (en) 2004-11-11
CA2524069C (en) 2011-11-08
PL1622880T6 (pl) 2018-08-31
AU2004233978B2 (en) 2010-02-11
MXPA05011707A (es) 2006-02-13
ES2284007T3 (es) 2007-11-01
EP1622880B1 (de) 2007-02-28
CY1106476T1 (el) 2012-01-25
BRPI0410029B8 (pt) 2021-06-15
JP4733631B2 (ja) 2011-07-27
PL1622880T3 (pl) 2007-08-31
ES2284007T7 (es) 2018-06-20
SI1622880T1 (sl) 2007-08-31
EP1622880A1 (de) 2006-02-08
DK1622880T3 (da) 2007-06-25
ATE355280T1 (de) 2006-03-15
JP2006525249A (ja) 2006-11-09
WO2004096778A1 (de) 2004-11-11
CO5700764A2 (es) 2006-11-30
NO2018022I1 (no) 2018-07-04
NZ543317A (en) 2008-05-30
NL300933I2 (nl) 2018-04-26
EG25273A (en) 2011-12-04
US7196086B2 (en) 2007-03-27
CY2018019I1 (el) 2018-12-12
DK1622880T6 (da) 2018-06-18
EP1622880B3 (de) 2018-05-23
UY28294A1 (es) 2004-11-30
CL2004000930A1 (es) 2005-03-18
PT1622880E (pt) 2007-06-04
FR18C1029I1 (https=) 2018-08-17

Similar Documents

Publication Publication Date Title
CN100393706C (zh) 具有抗病毒性能的取代二氢喹唑啉
TWI302835B (en) 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
CN106008322B (zh) 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
CN105153028B (zh) 作为c-Met激酶抑制剂的化合物
CN101184487A (zh) 作为抗菌剂的二环吡唑化合物
CN108299425A (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
US20050090496A1 (en) Sulphonyl compounds with 5-ht6 receptor affinity
RS51235B (sr) Derivati n-(aminoheteroaril)-1h-indol-2-karboksamida, njihovo dobijanje i njihova terapeutska primena
CN104725295B (zh) 芳杂环类衍生物及其在药物上的应用
AU718000B2 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
KR101179840B1 (ko) 치환 또는 무치환 아미노기를 도입한 4-피리딜알킬티오기를갖는 신규 고리형 화합물
TW382015B (en) Pyridin-3-yloxy-pyridin- or pyridazin-3-ylcarbamoyl-indoline derivatives having 5HT2c receptor antagonist activity, a process for the preparation thereof, and a pharmaceutical composition comprising them
CN114751858B (zh) 含有喹啉基的氨甲环酸衍生物及其制备与应用
JP4626353B2 (ja) 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
CN109232362A (zh) 芳杂环类衍生物及其在药物上的应用
CA2290475A1 (en) Indoline derivatives as 5ht2c receptor antagonists
WO1998047877A1 (en) 2-benzoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide derivatives and their use as inhibitors of hepatic production of apob-100
CN1918127B (zh) 具有引入了取代或无取代氨基的4-吡啶基烷硫基的环状化合物
JP2006117677A (ja) 新規のアリールピペラジン誘導体
HK1092463B (en) Substituted dihydrochinazolines having antiviral properties
CN100494177C (zh) 具有抗肿瘤活性的双酰胺基杂环类衍生物及其制备方法和用途
KR100486795B1 (ko) 5-ht-2c수용체길항제로유용한인돌린유도체
HK1200828A1 (en) Kinase inhibitors
JPH0395160A (ja) 二環式アミン化合物およびその製造法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1092463

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: AI LIMITED KUMARIS KG CO., LTD.

Free format text: FORMER OWNER: BAYER HEALTHCARE AG

Effective date: 20070608

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070608

Address after: Germany Wuppertal

Applicant after: AICURIS GmbH & Co.KG

Address before: Germany Leverkusen

Applicant before: Bayer Healthcare AG

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1092463

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171124

Address after: Germany Wuppertal

Patentee after: Eke Rees anti infection treatment Co.,Ltd.

Address before: Germany Wuppertal

Patentee before: AICURIS GmbH & Co.KG

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Germany Wuppertal

Patentee after: Akuris Anti-Infective Therapeutics AG

Address before: Germany Wuppertal

Patentee before: Eke Rees anti infection treatment Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230609

Address after: Germany Wuppertal

Patentee after: AIC246 JSC

Address before: Germany Wuppertal

Patentee before: Akuris Anti-Infective Therapeutics AG

CX01 Expiry of patent term

Granted publication date: 20080611

CX01 Expiry of patent term